Ovarian Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A stored tissue sample (from surgery or biopsy, preserved in a specific way called formalin-fixed paraffin-embedded, or FFPE) that contains a type of ovarian cancer called High Grade Serous Ovarian Cancer, and has enough material to be cut into multiple thin slices for testing.
- The stored tissue sample must be no older than 5 years, to ensure the quality is sufficient for analysis.
- The tissue sample must contain at least 100 living tumour cells.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Tissue samples that are either too old (collected more than 5 years ago) or too small or poor in quality (containing fewer than 100 living tumour cells per slice).
- Tissue that was collected after the patient had already received treatment with a drug called Mirvetuximab soravtansine, or any other therapy that targets a protein called FRα (folate receptor alpha).
- Tissue collected using a fine needle, or samples that are in liquid form, including fluid from the abdomen (called ascites).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: (847) 937-8000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Folate Receptor Alpha (FRa) Overexpression Immunohistochemistry (IHC)in Each Participating Sites (Local and Central)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.